Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis

BACKGROUND: Canagliflozin, an oral agent that inhibits sodium glucose co-transporter 2, improves glycemic control, body weight, and blood pressure and is generally well tolerated in patients with type 2 diabetes mellitus (T2DM). This study extends the scope of previous analyses by evaluating outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Buysman, Erin K., Chow, Wing, Henk, Henry J., Rupnow, Marcia F. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630836/
https://www.ncbi.nlm.nih.gov/pubmed/26527413
http://dx.doi.org/10.1186/s12902-015-0064-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630836/
https://www.ncbi.nlm.nih.gov/pubmed/26527413
http://dx.doi.org/10.1186/s12902-015-0064-8

Ejemplares similares